569426-U
Discovery® C8 (5 µm) HPLC Columns
L × I.D. 12.5 cm × 4 mm, HPLC Column
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
UNSPSC Code:
41115700
eCl@ss:
32110501
NACRES:
SB.52
L × i.d.:
12.5 cm × 4 mm
Particle size:
5 μm
Matrix active group:
C8 (octyl) phase
Pore size:
180 Å
Matrix:
silica gel, high purity, spherical base material, fully porous particle
Product Name
Discovery® C8 HPLC Column, 5 μm particle size, L × I.D. 12.5 cm × 4 mm
material
stainless steel column
Quality Level
agency
suitable for USP L7
product line
Discovery®
feature
endcapped
manufacturer/tradename
Discovery®
packaging
1 ea of
extent of labeling
7.5% Carbon loading
parameter
≤70 °C temp. range, 400 bar pressure (5801 psi)
technique(s)
HPLC: suitable, LC/MS: suitable
L × I.D.
12.5 cm × 4 mm
surface area
200 m2/g
surface coverage
3.4 μmol/m2
impurities
<10 ppm metals
matrix
silica gel, high purity, spherical base material, fully porous particle
matrix active group
C8 (octyl) phase
particle size
5 μm
pore size
180 Å
operating pH range
2-8
application(s)
food and beverages
separation technique
reversed phase
Features and Benefits
- Excellent reproducibility
- Faster separation of strongly hydrophobic analytes than C18 columns
- Stable, low-bleed LC-MS separations
- Exceptional peak shapes for basic and acidic compounds
- Compatible with low organic/highly aqueous mobile phases
Legal Information
Discovery is a registered trademark of Merck KGaA, Darmstadt, Germany
Still not finding the right product?
Explore all of our products under Discovery® C8 HPLC Column
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Related Content
General Care and Use of Supelco™ HPLC Columns
Discovery C18 and C8 HPLC Columns products offered
Scott C Bell et al.
Pharmacology & therapeutics, 145, 19-34 (2014-06-17)
With the discovery of the CFTR gene in 1989, the search for therapies to improve the basic defects of cystic fibrosis (CF) commenced. Pharmacological manipulation provides the opportunity to enhance CF transmembrane conductance regulator (CFTR) protein synthesis and/or function. CFTR
Bo-Rui Kang et al.
Bioorganic & medicinal chemistry letters, 25(24), 5808-5812 (2015-11-08)
2-Benzylisoquinolin-1(2H)-ones has been proposed as vasodilative agents on the basis of scaffold hopping. In the present study, a series of 2-benzylisoquinolin-1(2H)-ones were synthesized. Their vasodilative effects were evaluated by wire myograph on isolated rat mesenteric arterial ring induced contraction with
Hugo M Botelho et al.
Scientific reports, 5, 9038-9038 (2015-03-13)
Plasma membrane proteins are essential molecules in the cell which mediate interactions with the exterior milieu, thus representing key drug targets for present pharma. Not surprisingly, protein traffic disorders include a large range of diseases sharing the common mechanism of
Global Trade Item Number
| SKU | GTIN |
|---|---|
| 569426-U | 04061833301067 |
| 740683-1G | 04061832884394 |